Cognitive Behavioral Therapy Versus Antidepressant Medication in Generalized Anxiety Disorder: A Prospective Schematic & Meta-Analysis Approach
DOI:
https://doi.org/10.36283/ziun-pjmd14-3/076Keywords:
Cognitive Behavioral Therapy (CBT), Antidepressant Medication (ADM) , Generalized Anxiety Disorder (GAD), Clinical Decision-MakingAbstract
Background: Generalized Anxiety Disorder (GAD) is a common mental disorder, which is usually treated by cognitive behavioral therapy (CBT) or antidepressant medications (ADMs). Nevertheless, a significant number of patients do not respond well to monotherapy, resulting in complete remission. The present review focuses on the main comparison of CBT and ADM outcomes in GAD. Cases of combination therapy (CBT + ADM) were reviewed secondarily in those studies that reported it.
Methods: The articles were identified through systematic searches of PubMed and Google Scholar that were carried out to determine randomized controlled trials published between 2011 and 2025. The inclusion criteria included studies that used adults with standardized measurement of GAD diagnosis and post-therapeutic outcomes of anxiety measures CBT, and/or ADM. Combination data were identified where available. The mean anxiety scores were pooled in a random-effects meta-analysis and risk of bias was evaluated according to the Cochrane method.
Results: The number of included studies was eight randomized controlled trials with 259 participants. In the main analysis, CBT resulted in slightly improved post-treatment anxiety results (mean = 20.46, 95% CI: 5.9534.96) than pharmacotherapy alone (mean = 22.75, 95% CI: 4.6940.80). The lowest pooled score (mean = 17.72, 95% CI: 10.83 24.62) was observed in those studies that reported combination therapy. Nonetheless, because of great heterogeneity among the studies (I2 > 95%), the findings were viewed with caution. The overall direction of effect was supported by subgroup and sensitivity analyses.
Discussion: CBT can be slightly more effective than antidepressant drugs in alleviating anxiety symptoms in GAD. Combination therapy also demonstrated good outcomes in a few studies, but this was not the key aspect of this analysis. Future studies are needed on standardizing outcome measures and examining individual predictors of treatment responsiveness in order to conduct personalized care.
References
1. Ciraulo DA, Barlow DH, Gulliver SB, Farchione T, Morissette SB, Kamholz BW, et al. The effects of venlafaxine and cognitive behavioral therapy alone and combined in the treatment of co-morbid alcohol use-anxiety disorders. Beh Research and Therapy. 2013 Nov;51(11):729-735. doi:10.1016/j.brat.2013.08.003
2. Zugman A, Winkler AM, Qamar P, Pine DS. Current and Future Approaches to Pediatric Anxiety Disorder Treatment. AJP. 2024 Mar;181(3):189-200. doi:10.1176/appi.ajp.20231037
3. Heuzenroeder L, Donnelly M, Haby MM, Certer R, Andrews G, Vos T et al. Cost-Effectiveness of Psychological and Pharmacological Interventions for Generalized Anxiety Disorder and Panic Disorder. Aust N Z J Psychiatry. 2004 Aug;38(8):602-612. doi:10.1080/j.1440-1614.2004.01423.x
4. Dunlop BW, Polychroniou PE, Rakofsky JJ, Nemeroff CB, Craighead WE, Mayberg HS. Suicidal ideation and other persisting symptoms after CBT or antidepressant medication treatment for major depressive disorder. Psy Medicine. 2019 Sep;49(11):1869-1878. doi:10.1017/S0033291718002568
5. DeGeorge KC, Grover M, Streeter GS. Generalized anxiety disorder and panic disorder in adults. Am Fam Physician. 2022 Aug;106(2):157-64.
6. Boschloo L, Bekhuis E, Weitz ES, Reijnders M, J.DeRubeis R, Dimidjian S, et al. The symptom-specific efficacy of antidepressant medication vs. cognitive behavioral therapy in the treatment of depression: results from an individual patient data meta-analysis. Wor Psychiatry. 2019 May;18(2):183-191. doi:10.1002/wps.20630
7. Strawn JR, Mills JA, Suresh V, Peris TS, Walkup JT, Croarkin PE. Combining selective serotonin reuptake inhibitors and cognitive behavioral therapy in youth with depression and anxiety. J Affect Disord. 2022 Feb;298:292-300. doi:10.1016/j.jad.2021.10.047
8. Walter HJ, Bukstein OG, Abright AR, et al. Clinical Practice Guideline for the Assessment and Treatment of Children and Adolescents With Anxiety Disorders. J Am Acad Child Adolesc Psychiatry. 2020 Oct;59(10):1107-1124. doi:10.1016/j.jaac.2020.05.005
9. Garakani A, Murrough JW, Freire RC, Thom RP, Larkin K, Buono FD, et al. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options. Front Psychiatry. 2020 Dec;11. doi:10.3389/fpsyt.2020.595584
10. Zemestani M, Beheshti N, Rezaei F, Heiden C van der, Kendall PC. Cognitive Behavior Therapy Targeting Intolerance of Uncertainty Versus Selective Serotonin Reuptake Inhibitor for Generalized Anxiety Disorder: A Randomized Clinical Trial. Beha Change. 2021 Sep;38(4):250-262. doi:10.1017/bec.2021.16
11. Scholten W, Batelaan N, Van Balkom A. Barriers to discontinuing antidepressants in patients with depressive and anxiety disorders: a review of the literature and clinical recommendations. Ther Adv Psychopharmacol. 2020 Jun;10:2045125320933404. doi:10.1177/2045125320933404
12. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. bmj. 2021 Mar 29;372. doi:10.1136/bmj.n71.
13. Fekete JT, Győrffy B. MetaAnalysisOnline. com: web-based tool for the rapid meta-analysis of clinical and epidemiological studies. J Med Internet Res 2025 Mar;27:e64016. doi: 10.2196/64016.
14. Crits-Christoph P, Newman MG, Rickels K, Gallop R, Gibbons MB, Hamilton JL, Ring-Kurtz S, Pastva AM. Combined medication and cognitive therapy for generalized anxiety disorder. J Anxiety Disord. 2011 Dec 1;25(8):1087-94. Doi: 10.1016/j.janxdis.2011.07.007.
15. LoParo D, Dunlop BW, Nemeroff CB, Mayberg HS, Craighead WE. Prediction of individual patient outcomes to psychotherapy vs medication for major depression. npj Ment Health Res. 2025 Feb 5;4(1):4. Doi: 10.1038/s44184-025-00119-9.
16. Wetherell JL, Stoddard JA, White KS, Kornblith S, Nguyen H, Andreescu C, Zisook S, Lenze EJ. Augmenting antidepressant medication with modular CBT for geriatric generalized anxiety disorder: a pilot study. Int J Geriatr Psychiatry. 2011 Aug;26(8):869-75. Doi: 10.1002/gps.2619.
17. Dunlop BW, LoParo D, Kinkead B, Mletzko-Crowe T, Cole SP, Nemeroff CB, Mayberg HS, Craighead WE. Benefits of sequentially adding cognitive-behavioral therapy or antidepressant medication for adults with nonremitting depression. Am J Psychiatry. 2019 Apr 1;176(4):275-86. Doi: 10.1176/appi.ajp.2018.18091075.
18. Wetherell JL, Petkus AJ, White KS, Nguyen H, Kornblith S, Andreescu C, Zisook S, Lenze EJ. Antidepressant medication augmented with cognitive-behavioral therapy for generalized anxiety disorder in older adults. Am J Psychiatry. 2013 Jul;170(7):782-9. Doi: 10.1176/appi.ajp.2013.12081104
19. Sevi Tok ES, Arkar H, Bildik T. The Effectiveness of Cognitive Behavioral Therapy, Medication, or Combined Treatment For Childhood Anxiety Disorders. Turk Psikiyatri Derg. 2016 Jun 1;27(2). Doi: 10.5080/u13697.
20. Markell HM, Newman MG, Gallop R, Gibbons MB, Rickels K, Crits-Christoph P. Combined medication and CBT for generalized anxiety disorder with African American participants: Reliability and validity of assessments and preliminary outcomes. Behav Ther. 2014 Jul 1;45(4):495-506. Doi: 10.1016/j.beth.2014.02.008.
21. Rosnick CB, Wetherell JL, White KS, Andreescu C, Dixon D, Lenze EJ. Cognitive-behavioral therapy augmentation of SSRI reduces cortisol levels in older adults with generalized anxiety disorder: A randomized clinical trial. J Consult Clin Psychol. 2016 Apr;84(4):345. Doi: https://doi.org/10.1037/a0040113.
22. Pelissolo A, Abou Kassm ,Sandra, and Delhay L. Therapeutic strategies for social anxiety disorder: where are we now? Expert Rev Neurother. 2019 Sep;19(12):1179-1189. doi:10.1080/14737175.2019.1666713
23. Burkhouse KL, Jimmy J, Defelice N, Klumpp H, Ajilore O, Hosseini B, et al. Nucleus accumbens volume as a predictor of anxiety symptom improvement following CBT and SSRI treatment in two independent samples. Neuropsychopharmacol. 2020 Nov;45(3):561-569. doi:10.1038/s41386-019-0575-5
24. Nicotra CM, Strawn JR. Advances in Pharmacotherapy for Pediatric Anxiety Disorders. Child Adolesc Psychiatr Clin. 2023 Jul;32(3):573-587. doi:10.1016/j.chc.2023.02.006
25. Smárason O, Skarphedinsson G, Storch EA. Cognitive Behavioral Therapy for Anxiety and Depression in Children and Adolescents. Psychiatr Clin. 2024 Jun;47(2):311-323. doi:10.1016/j.psc.2024.02.002
26. Impey B, Gordon RP, Baldwin DS. Anxiety disorders, post-traumatic stress disorder, and obsessive–compulsive disorder. Medicine. 2020 Nov;48(11):717-723. doi:10.1016/j.mpmed.2020.08.005
27. Melvin GA, Gordon MS. Antidepressant Medication: Is It a Viable and Valuable Adjunct to Cognitive-Behavioral Therapy for School Refusal? Cogn Behav Pract. 2019 Feb;26(1):107-118. doi:10.1016/j.cbpra.2018.07.005
28. Santomauro DF, Purcell C, Whiteford HA, Ferrari AJ, Vos T. Grading disorder severity and averted burden by access to treatment within the GBD framework: a case study with anxiety disorders. Lancet Psychiatry. 2023 Apr;10(4):272-281. doi:10.1016/S2215-0366(23)00037-8
29. Creswell C, Waite P, Hudson J. Practitioner Review: Anxiety disorders in children and young people – assessment and treatment. J Child Psychol Psychiatry. 2020 Jan;61(6):628-643. doi:10.1111/jcpp.13186
30. Koyuncu A, İnce E, Ertekin E, Tükel R. Comorbidity in social anxiety disorder: diagnostic and therapeutic challenges. Drugs Context. 2019 Apr; 8:212573. doi:10.7573/dic.212573
31. Abubakar AR, Sani IH, Malami S, Yaro AM, Jahan I, Adnan N, et al. Anxiety Disorders: Recent Global Approach to Neuro-pathogenesis, Drug Treatment, Cognitive Behavioral Therapy, and Their Implications. Bangladesh J Med Sci. 2021 Apr; 20(3):487-503. doi:10.3329/bjms.v20i3.52790
32. Sigurvinsdóttir AL, Jensínudóttir ,Kolbrún Björk, Baldvinsdóttir ,Karen Dögg, Smárason ,Orri, and Skarphedinsson G. Effectiveness of cognitive behavioral therapy (CBT) for child and adolescent anxiety disorders across different CBT modalities and comparisons: a systematic review and meta-analysis. Nord J Psychiatry. 2020 Apr; 74(3):168-180. doi:10.1080/08039488.2019.1686653
33. Hudson JL, McLellan LF, Eapen V, Rapee RM, Wuthrich V, Lyneham HJ. Combining CBT and sertraline does not enhance outcomes for anxious youth: a double-blind randomised controlled trial. Psychological Med. 2023 Aug; 53(5):1741-1749. doi:10.1017/S0033291721003329
34. Adolph D, Teismann T, Wannemüller A, Margraf J. Fear conditioning and extinction learning in the mood and anxiety disorders spectrum – Associations with the outcome of cognitive behavior therapy. Behav Res Ther. 2023 Jan; 160:104229. doi:10.1016/j.brat.2022.104229
35. Norton PJ, Provencher MD, Kilby CJ, Roberge P. Impact of group transdiagnostic cognitive-behavior therapy for anxiety disorders on comorbid diagnoses: Results from a pragmatic randomized clinical trial in primary care. Depress Anxiety. 2021 Jun; 38(7):749-756. doi:10.1002/da.23184
36. Allgulander C, Florea I, Huusom AK. Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol. 2006 Oct 1;9(5):495-505. doi: 10.1017/S1461145705005973.
37. Baumel WT, Lu L, Huang X, Drysdale AT, Sweeny JA, Gong Q, et al. Neurocircuitry of treatment in anxiety disorders. Biomark Neuropsychiatry. 2022 Jun;6:100052. doi: 10.1016/j.bionps.2022.100052.
38. Metts AV, Yarrington JS, Zinbarg R, Hammen C, Mineka S, Enders C, et al. Early-life adversity and risk for depression and anxiety: The role of interpersonal support. Dev Psychopathol. 2023 May;35(2):863-875. doi: 10.1017/S0954579422000116.
39. Gkintoni E, Vassilopoulos SP, Nikolaou G, Boutsinas B. Digital and AI-Enhanced Cognitive Behavioral Therapy for Insomnia: Neurocognitive Mechanisms and Clinical Outcomes. J Clin Med. 2025 Mar 26;14(7):2265. doi: 10.3390/jcm14072265.
40. Tanguay-Sela M, Rollins C, Perez T, Qiang V, Golden G, Tunteng JF, et al. A systematic meta-review of patient-level predictors of psychological therapy outcome in major depressive disorder. J Affect Disord. 2022 Nov 15;317:307-318. doi: 10.1016/j.jad.2022.08.041.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Pakistan Journal of Medicine and Dentistry
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access article distributed under the terms of the CreativeCommons Attribution License (CC BY) 4.0 https://creativecommons.org/licenses/by/4.0/
Metrics
How to Cite
